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Edited by Angel NebredaAbstract PTPRO is often silenced by DNA hypermethylation
in primary human tumors and cancer cell lines and functions
as a tumor suppressor. Here we show that PTPRO is a target
of E2F1. In addition, the microRNA cluster miR-17-92, another
target of E2F1, participates in PTPRO regulation. PTPRO
mRNA was up-regulated during S phase in synchronized HeLa
cells and in vitro PTPRO promoter activity is high in early S
phase while the PTPRO 3 0UTR reporter activity is low in late
S phase. This study provides evidence that the PTPRO gene is
co-regulated by both E2F1 and miR-17-92.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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PTPRO is a member of the family of receptor-type protein
tyrosine phosphatases (RPTPs) [1]. There are six known
mRNA variants of human PTPRO [2]. The two major tran-
scripts are the full-length PTPRO and the truncated PTPRO
(PTPROt) [3]. The full-length PTPRO cDNA encodes a recep-
tor-type PTP with a single intracellular catalytic domain, a
transmembrane region, and an extended extracellular domain
containing eight repeats of ﬁbronectin type III-like motifs.
The full-length PTPRO transcript is expressed at a very high
level in kidney and brain, and at low levels (relative to brain
and kidney) in almost all other tissues and cell lines [4]. In
addition, the PTPRO gene is frequently found methylated in
a tumor-speciﬁc manner [2,4,5]. Overexpressed PTPRO in
A549 cells functions as a candidate tumor suppressor [4].
The transcription factor E2F1 plays a critical role in cell cy-
cle control and aﬀects cell proliferation by regulating the
expression of target genes, whose products are required for S
phase entry and progression [6]. The activity of E2F is regu-
lated principally through association with co-activators such
as p300/CBP [7,8], and co-repressors such as the retinoblas-
toma protein RB [9]. MicroRNAs (miRNAs) are a class of
naturally occurring small non-coding RNAs that regulate gene
expression by translational repression or mRNA cleavage [10].
The miR-17-92 cluster functions as an oncogene in human and
other animal models [11–13]. To date, many targets of miR-17-*Corresponding author. Fax: +86 431 85099768.
E-mail addresses: luj809@nenu.edu.cn, ycsuo@nenu.edu.cn (J. Lu).
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two recent papers suggested that endogenous E2F1, E2F2
and E2F3 directly bind the promoter of the miR-17-92 cluster
activating its transcription, implying an auto-regulatory feed-
back loop between E2F factors and miRNAs from the miR-
17-92 cluster [15,16].
We report here a transcriptional mechanism mediated by the
E2F1 protein, that up-regulates PTPRO, as well as a post-tran-
scriptional mechanism mediated by the miR-17-92 cluster that
leads to the down-regulation of PTPRO in cell cycle progres-
sion.2. Materials and methods
2.1. Bioinformatics
The TRANSFAC program (http://www.gene-regulation.com/) was
used to search the putative transcription factor binding elements in hu-
man PTPRO gene promoter, and the Targetscan (http://genes.mit.edu/
tscan/targetscanS.html) was used to screen miRNAs potentially target-
ing the 3 0UTR of human PTPRO gene.
2.2. Plasmids
Two fragments of 922 and 392 bp, corresponding to the 5 0 upstream
region of the human PTPRO gene, were ampliﬁed by PCR and cloned
into pGL3-basic vector (Promega, USA) upstream of the Photinus
pyralis luciferase reporter gene to construct the pGL3-922 and
pGL3-392 reporters, respectively. The PTPRO promoter reporters
with mutations in E2F1 binding sites (pGL3-M1, pGL3-M2 and
pGL3-M1/2) were generated using PCR-mediated site-directed muta-
genesis. A 140 bp 3 0UTR fragment of the PTPRO gene was ampliﬁed
by PCR and cloned into pGL3-basic, pGL3-392 and pGL3-922 down-
stream from the stop codon of luciferase to construct the pGL3-Basic-
UTR, pGL3-392-UTR and pGL3-922-UTR, respectively. Reporters
of PTPRO 3 0UTR (pGL3-Basic-UTR Mut, pGL3-392-UTR Mut
and pGL3-922-UTR Mut) with mutations in the miR-17-92 target site
were generated using PCR-mediated site-directed mutagenesis. All
constructs were veriﬁed by sequencing. The following plasmids have
been previously described: pcDNA3.1 (Invitrogen), pcDNA3-E2F1,
pcDNA3-E2F1 Mut [17]; and pCMV, pCMV-miR-17-92 [13]. The
constructs of p300 (pCI-p300) and p300DHAT provided by Dr. Joan
Boyes (Institute of Cancer Research, UK).
2.3. Cell culture, transfection and reporter gene assays
Human embryonic kidney 293T cells and HeLa cells were main-
tained in Iscoves modiﬁed Dulbeccos medium supplemented with
10% fetal calf serum, 100 lg/ml penicillin and 100 lg/ml streptomycin.
For transfection of 293T cells, a conventional calcium phosphate
method was used. The transfection of HeLa cells was done by using
Lipofectamine 2000 (Invitrogen) according to the manufacturers
instructions. Luciferase assays were performed using the Promega
Luciferase Assay Kit following the manufacturers instructions. Activ-
ities of ﬁreﬂy (experimental) and Renilla (control) luciferases were mea-
sured in a Turner Designs TD20/20 Luminometer (USA). Promoter
strengths were quantiﬁed by calculating the ratio of ﬁreﬂy/Renilla
luciferase activity of the same lysate sample.blished by Elsevier B.V. All rights reserved.
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Total RNA isolation and reverse transcription reaction were per-
formed by using the RNA extraction and RT Systems supplied by Pro-
mega. The quantitative real-time PCR was done on an ABIPRISM
7100 Sequence Detection System following the manufacturers proto-
col, and SYBR Green (TaKaRa, Japan) was used as a double-stranded
DNA-speciﬁc ﬂuorescent dye. b-Actin was used for standardizing
PTPRO mRNA expression. Ampliﬁcation primers were 5 0-
GGGGATGATACAACGGACTT-30 and 5 0-ACCATTGTTGAGA-
CGGCTATGAACG-3 0 for PTPRO, 5 0-TCGTGCGTGACATTAAG-
GAG-3 0 and 5 0-ATGCCAGGGTACATGGTGGT-3 0 for b-actin.
Data were analyzed by calculating the 2-DDCt. All the results represent
means ± S.D. of three independent experiments. For microRNA detec-
tion, mature miRNAs were assayed using the single-tube Taq-Man
MicroRNA Assays and the Gene Expression Assays, respectively, fol-
lowing the manufacturers instructions (Applied Biosystems, Foster
City, CA). All RT reactions, including no-template controls and RT
minus controls, were run in a GeneAmp PCR 9700 Thermocycler (Ap-
plied Biosystems). Samples were normalized to an endogenous control
(U6snRNA). Gene expression levels were quantiﬁed using the
MX3000P Real-time PCR Instrument (Stratagene, USA). Compara-
tive real-time PCR was performed in triplicate, including no-template
controls. Relative expression was calculated using the comparative Ct
method.
2.5. Western blotting
Cultured cells were lysed with NP40 lysis buﬀer. The protein concen-
tration in the extracts was determined using a Protein Assay System
reagent (Bio-Rad). Samples were resuspended in loading buﬀer. Equal
loading of proteins were electrophorezed on 6% SDS–PAGE (for
PTPRO) or 12% (for other proteins) and transferred to PVDF mem-
branes. PTPRO was detected using the aﬃnity-puriﬁed polyclonal
IgY antibody (Genway Biotech Inc.), and the speciﬁc signals were de-
tected using an ECL detection system (Pierce Int.). Antibody for
detecting actin was purchased from Pierce.
2.6. Electrophoretic mobility shift assay (EMSA)
The nuclear extracts were prepared using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents. The sequences of the sense strand
oligonucleotides used in EMSA were 5 0-AACTGGGATCTGG-
CGCCTGGATTG-3 0 for 376/368 site, 5 0-AGCATGCGCTCGC-
CAGGAGCAACCT-3 0 for +54/+63 site and 5 0-GGCCGCCTTTGG-
CGCCAAAGACAGCC-30 for E2F1 binding sites in p73 promoter as
a positive control. The E2F1 binding sites are underlined. The se-
quences with E2F1 binding sites mutations were 5 0-AACTGGGAT-
CTGATGCCTGGATTG-3 0 for 376/368 site, 5 0-AGCATGCG
CTATCCAGGAGCAACCT-30 for +54/+63 site and 5 0-GGCCGCC-
TTTGGATCCAAAGACAGCC-30 for E2F1 binding sites mutations
in p73 promoter, where the nucleotide substitutions are in bold. Label-
ing of probes and the EMSA were performed following the instruc-
tions for Biotin 3 0 End DNA Labeling Kit and lightShift
Chemiluminescent EMSA Kit purchased from Pierce.
2.7. Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out using a kit supplied by Upstate follow-
ing the manufacturers protocol. The primers used to detect PTPRO
promoter sequences were 5 0-TTGTGCTATTTGTTCCTGGGTG-3 0
and 5 0-CATTGCAGACTCCGCCTCA-3 0. The primers used to detect
human GAPDH promoter were 5 0-TACTAGCGGTTTTA-
CGGGCG-30 and 5-TCGAACAGGAGGAGCAGAGAGCGA-3 0.
PCR ampliﬁcation conditions were 94 C for 30 s, 54.5 C for 30 s
and 72 C for 30 s, for 33 cycles. Antibody against E2F1 (cat. #05-
379) was purchased from Upstate Biotechnology.
2.8. Cell synchronization and ﬂuorescence-activated cell sorter analysis
HeLa cells were synchronized for S phase using double thymidine
treatment. Cells were treated with 2 mM thymidine for 19 h, followed
by a 10 h release in fresh medium and successive re-treatment with the
drug for 16 h. Cells were then washed three times with PBS and cul-
tured in fresh medium. Cells were harvested at appropriate time points
and assayed for cell cycle distribution. The results shown are the means
of three assays. For ﬂuorescence-activated cell sorter analysis cells were
harvested, washed twice with PBS, and ﬁxed in 70% ethanol. The ﬁxed
cells were washed twice with PBS and treated with RNase A andstained with propidium iodide (PI). The cell cycle status was deter-
mined by using a Becton–Dickinson FACScan instrument and ana-
lyzed with Cell Quest software.3. Results and discussion
3.1. PTPRO was regulated by E2F1
PTPRO is a classical receptor-type protein tyrosine phos-
phatase (RPTP) playing a role in tumor suppression. Never-
theless, little is known about how the PTPRO gene is
regulated. In this study, we wanted to elucidate the regulatory
mechanisms of PTPRO gene. Considering that PTPRO inter-
feres with normal cell cycle progression by retarding the re-en-
try of cells into S phase [4], we wondered if E2F1, a key
regulator of G1/S transition, could target PTPRO. Examina-
tion of changes in endogenous PTPRO mRNA upon E2F1
overexpression in 293T cells showed that ectopically expressed
E2F1 increased the endogenous PTPRO mRNA level (Fig.
1A). Next, we tested the responsiveness of PTPRO promoter
to E2F1. We cloned the two human PTPRO promoter frag-
ments (392 and 922 bp) into luciferase reporter plasmids
(Fig. 1B, pGL3-392, pGL3-922). Transfection of each of the
two reporters with an E2F1 expression vector into 293T cells
resulted in E2F1-induced activation of these promoters (Fig.
1C). Similar results were observed in HeLa cells (data not
shown). These results suggest that the transcription of PTPRO
is regulated by E2F1. In addition, it is possible that other tran-
scription factors may also be responsible for the transcrip-
tional regulation of PTPRO. We identiﬁed candidate
transcriptional regulators of PTPRO by bioinformatic ap-
proaches. For example, Sp1 could signiﬁcantly activate the
PTPRO promoter (unpublished data).
3.2. Identiﬁcation of E2F1 regulatory elements at the PTPRO
promoter
To identify the elements in PTPRO promoter responsive to
E2F1 we chose two putative E2F1 binding sites (376/368
and +54/+63). To examine the contribution of each of the
two sites to the activation of PTPRO promoter, we generated
point mutations in these two sites, either individually or in
combination (Fig. 2A), and tested the activation of the
PTPRO promoter reporters upon E2F1 protein overexpres-
sion. As shown in Fig. 2B, mutation of either putative E2F1
binding sites partially decreased the E2F1-activation of the
PTPRO promoter. Double mutation of both putative E2F1
binding sites further abolished the E2F1-activation, indicating
that both putative E2F1 binding sites contributed to the regu-
lation of the PTPRO promoter. We obtained the same results
in HeLa cells (data not shown). To investigate whether E2F1
could bind directly to the putative E2F1 binding sites, we per-
formed gel mobility shift assay by incubating biotin-labeled
oligonucleotides containing E2F1 binding site A (376/
368) or B (+54/+63) with nuclear extracts from E2F1-overex-
pressed 293T cells. As shown in Fig. 2C, E2F1 bound to both
the two wild-type oligonucleotides (lanes 2 and 6), but not to
the E2F1-mutated oligonucleotides (lanes 3 and 7). Moreover,
addition of excess of unlabeled oligonucleotides containing a
consensus E2F1 binding site (WT) abolished formation of
the shift bands (lanes 4 and 8). As a positive control, a 26 bp
probe from the p73 promoter, a known E2F1 target, was
included in the experiments (data not shown). To further
Fig. 1. PTPRO was transcriptonally regulated by E2F1. (A) Real-time PCR analysis of PTPRO mRNA in 293T cells 48 h after transfection with
E2F1. Data are expressed as fold induction over the empty vector pcDNA3.1. (B) Schematic representation of the 922 bp PTPRO promoter pGL3-
922 and 392 bp PTPRO promoter pGL3-392. The binding sites for E2F1 are indicated. The luciferase gene (Luc) used for promoter activity is also
indicated. The positions of the PTPRO promoter fragments and E2F1 binding sites are numbered relative to the transcription initiation site (+1). (C)
293T cells were transfected with the indicated reporter constructs together with pcDNA3.1 or E2F1. The transfected cells were treated as described in
Section 2 to determine the eﬀects of E2F1 stimulation. Values represent relative luciferase activities compared with promoter activity versus PREP7.
Error bars represent the standard deviation obtained with triplicate samples.
Fig. 2. Identiﬁcation of E2F regulatory elements at the PTPRO promoter. (A) Schematic representation of the PTPRO promoter mutants. (B) 293T
cells were transfected with the indicated reporter constructs together with pcDNA3.1 or E2F1. The luciferase activity was analyzed as in Fig. 1C. (C)
Nuclear extracts were prepared from E2F1 overexpressed 293T cells, and mobility shift assays were performed using biotin-labeled oligonucleotides
consisting of PTPRO promoter sequence (376/368 site and +54/+63 site), or mutant sequences. Unlabeled oligonucleotides (wild-type) at 100-fold
molar excess were used to compete for E2F1 binding. (D) Cross-linked chromatin complexes were immunoprecipitated with anti-E2F1 or IgG
antibody. Co-precipitated DNA sequences were ampliﬁed using primers speciﬁc for the PTPRO and GAPDH promoters. PTPRO promoter
fragments were immunoprecipitated from 293T cells using an anti-E2F1 antibody.
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tain whether E2F1 binds to the PTPRO promoter in vivo. As
shown in Fig. 2D, PCR primers that span the region 376/
368 site of the PTPRO promoter clearly detected PTPRO
promoter DNA in ChIP samples precipitated by an E2F1 anti-
body. These data clearly demonstrate that E2F1 interacts with
PTPRO promoter in vitro and in vivo. Collectively, our dataindicate that PTPRO is a new target of E2F1. Since many
E2F1-targeted genes have been shown to be involved in G1/
S transition [6], and PTPRO interferes with normal cell cycle
progression by retarding the re-entry of cells into S phase in
A549 cells [4], we speculate that PTPRO may be able to aﬀect
G1/S transition. However, further investigation is needed to
clarify this function of PTPRO.
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activating PTPRO promoter
p300 and CBP were reported to interact with the activation
domain of E2F1 and stimulate E2F1-mediated activation asFig. 4. PTPRO was post-transcriptonally regulated by miR-17-92. (A) Bio
transcript. (B) Schematic representation of the PTPRO 3 0UTR reporter c
indicated. Luciferase activities were measured as in Fig. 1D. (D) and (E) 293T
PTPRO expression was determined by real-time PCR (D) and Western blottin
17-92, and E2F1 expression was determined by Western blotting. (G) 293T c
cross-linked chromatin complexes were immunoprecipitated with anti-E2F1
speciﬁc for the PTPRO mentioned in Fig. 2D. PTPRO promoter fragments
Fig. 3. Acetylated E2F1 activated PTPRO promoter. (A) 293T cells were tra
E2F1, p300 and p300DHAT, either individually or in combination as indicat
together with pcDNA3.1, E2F1 or E2F1 Mut. The luciferase activity was anco-activators [18]. We were interested in testing whether p300
could activate the PTPRO promoter and whether the acetylase
activity of p300 was necessary for its action. First, 293T cells
were transfected with the 922 bp PTPRO promoter pGL3-informatic prediction of interaction between miR-17-92 and PTPRO
onstructs. (C) 293T cells were transfected with diﬀerent reporters as
cells were transfected with pCMV empty vector or miR-17-92, and the
g (E). (F) 293T cells were transfected with pCMV empty vector or miR-
ells were transfected with pCMV empty vector or miR-17-92, then the
or IgG antibody. Co-precipitated DNAs were ampliﬁed using primers
were immunoprecipitated using an anti-E2F1 antibody.
nsfected with the 922 bp PTRPO promoter, together with pcDNA3.1,
ed. (B) 293T cells were transfected with the 922 bp PTRPO promoter,
alyzed as in Fig. 1C.
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ally or in combination, as illustrated in Fig. 3A. It can be seen
that the luciferase activity was enhanced by p300 while the
p300DHAT did not have this eﬀect. This result suggested thatFig. 5. PTPRO was co-regulated by E2F1 and miR-17-92. (A) 293T cells we
E2F1 and luciferase activities were measured as in Fig. 1D. (B) HeLa cells w
were measured using a Becton–Dickinson FACScan instrument and Cell Que
in synchronized HeLa cells at the indicated time. Data are expressed as fold
protein level in synchronized HeLa cells at the indicated time. (E) and (F
synchronized HeLa cells at the indicated time. Data are expressed as fold ind
various reporter constructs as indicated. Cells were treated with thymidine 18
cells were assayed for cell cycle distribution and luciferase activities at the tithe HAT activity of p300 was necessary for its action. Similar
results were seen when using two other acetylases, CBP and
PCAF (data not shown). We next examined whether the acet-
ylation of E2F1 was involved in activation of the PTPRO pro-re transfected with reporters as indicated, together with pcDNA3.1 or
ere synchronized as described in Section 2, and cell cycle distributions
st software. (C) Real-time PCR determination of PTPRO mRNA level
induction over control. (D) Western blotting determination of E2F1
) Real-time PCR determination of miR-17-5p and miR-20a levels in
uction over the control. (G) and (H) HeLa cells were transfected with
h after transfection for synchronization. After double thymidine block
me indicated.
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mutant form of E2F1 that cannot be acetylated [17]), was able
to activate the 922 bp PTPRO promoter. These experiments
implicated that acetylation of E2F1 was important for its acti-
vation of the PTPRO promoter.3.4. PTPRO was post-transcriptionally regulated by miR-17-92
As depicted in Fig. 1A and C, E2F1 strongly activated the
PTPRO promoter, while it only slightly increased PTPRO
mRNA levels. This diﬀerence may be indicative of possible
involvement of post-transcriptional mechanism(s) that caused
further down-regulation of the gene. We used bioinformatic
approaches to search for potential miRNA targets, and an on-
line search of the Targetscan database demonstrated that three
putative miRNA (miR-17-92, miR-133 and miR-25/32/92/167)
target sites were harbored in the 3 0UTR of the PTPRO
mRNA. Considering the recently ﬁnding of an auto-regulatory
feed-back loop between E2F factors and miRNAs from the
miR-17-92 cluster [15,16], we decided to focus on miR-17-92
(Fig. 4A). First, we inserted a portion of the PTPRO 3 0UTR
harboring the putative miR-17-92 target site to the down-
stream of stop codon of pGL3-basic, pGL3-922 and pGL3-
392, respectively. We also constructed pGL3-Basic-UTR
Mut, pGL3-922-UTR Mut and pGL3-392-UTR Mut plas-
mids, containing the mutated miR-17-92 binding site of
PTPRO 3 0UTR (Fig. 4B). The transfection results in 293T cells
showed that the luciferase activity from PTPRO 3 0UTR WT
reporter was approximately 50% of the empty vector, while
the luciferase activity from PTPRO 3 0UTR Mut reporter was
rescued (Fig. 4C). The same results were observed in HeLa
cells (data not shown). We used pGL3-Control carrying the
PTPRO 3-UTR to examine the contribution of miR-17-92 to
the expression of PTPRO 3-UTR reporters. The results from
reporter assays were consistent with the results shown in Fig.
4C, however, the diﬀerences between pGL3-control empty vec-
tor, pGL3-control-UTR, pGL3-control-UTRmut were very
small, perhaps due to the strong activity of SV40 promoter
in pGL3-control (Suppl. Fig. 1). To ﬁnd out whether miR-
17-92 aﬀected the endogenous PTPRO protein and mRNA
levels, we examined the eﬀects of this miRNA in 293T cells.
Western blotting from protein extracts of 293T cells revealed
a dramatic reduction in the PTPRO protein after pCMVp-
uro-miR-17-92 transfection, compared with the empty vector
(Fig. 4E). In addition, Fig. 4D shows that miR-17-92 also
down-regulates PTPRO mRNA expression. Considering that
E2F1 is also a target of miR-17-92, it is possible that expres-
sion of miR-17-92 reduced E2F1 levels and thus indirectly al-
tered the expression of PTPRO. So we adopted Western
blotting and real-time PCR to clarify the inﬂuence of over-
expression of miR-17-92 on both mRNA and protein levels
of E2F1. We found that over-expression of miR-17-92 down-
regulated the E2F1 protein (Fig. 4F) but not mRNA levels
(data not shown). Our ChIP experiments also showed that
over-expression of miR-17-92 did not obviously decrease the
abundance of E2F1 on the PTPRO promoter (Fig. 4G). These
data indicate that PTPRO is a target of miR-17-92.3.5. PTPRO was co-regulated by E2F1 and miR-17-92
We then wanted to know if E2F1 and miR-17-92 were simul-
taneously involved in PTPRO regulation in cell cycle progres-
sion. We ﬁrst compared the response of diﬀerent reporters(pGL3-922, pGL3-922-UTR WT, pGL3-922-UTR Mut) to
E2F1. We discovered that the promoter reporters inserted with
the PTPRO 3 0UTR responded more weakly to E2F1 activation
(Fig. 5A). E2F1 was comparable in all co-transfections (Suppl.
Fig. 2). Fabio et al. recently reported that when AGS gastric
cancer cells arrested in mitosis were released and re-entered
the G1 phase, the expression of the miR-106b, miR-93 and
miR-25 precursor RNAs were up-regulated and this process
was directly associated with E2F1 expression [19]. Therefore,
it is possible that the overexpressed E2F1 ﬁrst up-regulated
PTPRO mRNA and then down-regulated PTPRO protein
expression by up-regulating miR-17-92 transcription, leading
to the above phenomenon in reporter assays. E2F1 overexpres-
sion indeed upregulated miR-17-5p, a member of the miR-17-
92 cluster (Suppl. Fig. 3). To further validate the co-regulation
of PTPRO by E2F1 and miR-17-92 in cell cycle progression, we
ﬁrst monitored PTPRO mRNA expression in synchronized
HeLa cells (Fig. 5B), and found that PTPRO transcription
was up-regulated during S phase (Fig. 5C). Then, we examined
the expression proﬁles of E2F1 and two miR-17-92 members:
miR-17-5p and miR-20a in synchronized HeLa cells. We found
that both E2F1mRNA (Suppl. Fig. 4) and protein were up-reg-
ulated in G1 phase (2 h) (Fig. 5D). In addition, we found that
expression of miR-17-5p was high in late S phase (6 h) whereas
the expression of miR-20a was low after being released from
double-thymidine arrest (Fig. 5E and F). These results demon-
strated a positive correlation between E2F1 and PTPRO and a
negative correlation between the miR-17-92 cluster, especially
miR-17-5p and PTPRO. Finally, we examined the activities
of the wild-type and E2F1 site-mutated PTPRO promoters dur-
ing diﬀerent phases of the cell cycle. We found that the PTPRO
promoter activity was low in G0 and early G1 phase cells (0 h
released from double-thymidine arrest), and it was markedly
up-regulated in late G1/early S phase cells (4 h) (Fig. 5G). This
observation is consistent with PTPRO mRNA expression in
synchronized HeLa cells. Mutations in the E2F1 binding sites
reduced the activation of the promoter, demonstrating that
both E2F1 binding sites contributed to the activation of the
PTPRO promoter at the G1/S phase boundary. We also exam-
ined the activities of the wild-type and miR-17-92 site-mutated
PTPRO 3 0UTR reporter in diﬀerent phases of synchronized
HeLa cells. We observed that the reporter activity of pGL3-Ba-
sic-UTR WT was down-regulated in late S phase cells (6 h),
whereas the activity of pGL3-Basic-UTR Mut was rescued
(Fig. 5H). These results indicated that the miR-17-5p binding
site in the PTPRO 3 0UTR reporter contributed to the inhibition
of the reporter during late S phase. Therefore, our data suggeste
a model where PTPRO is co-regulated by E2F1 andmiR-17-92.
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